Dr. Minna is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5323 Harry Hines Blvd
Dallas, TX 75390Phone+1 214-645-8600
Summary
- Dr. Minna is Director of the Hamon Center for Therapeutic Oncology Research, and Professor of Internal Medicine and Pharmacology at The University of Texas Southwestern Medical Center (1991-present). He holds the Max L. Thomas Distinguished Chair in Molecular Pulmonary Oncology and the Sarah M. and Charles E. Seay Distinguished Chair in Cancer Research. He graduated from Stanford Medical School (research under Leonard Herzenberg), was a resident at Massachusetts General Hospital, a Research Associate at the NIH (under Dr. Marshal Nirenberg), Chief of the Section of Somatic Cell Genetics, Chief of the NCI-VA and then NCI-Navy Medical Oncology Branches at the National Cancer Institute (1975-1991). His work focuses on understanding the molecular pathogenesis of lung cancer and translating this into the clinic by identifying and targeting acquired lung cancer vulnerabilities. He has trained many investigators in lung cancer research. He has led a joint Lung Cancer NCI Special Program of Research Excellence (SPORE) grant between UTSW and the MD Anderson Cancer Center for 25 years. His publications have an H-Index of 193, and a D-Index of 179 with some 130,000 citations.
Education & Training
National Heart Lung and Blood Institute (NHLBI)Post-Doctoral Fellowship, 1969 - 1973
Massachusetts General HospitalResidency, Internal Medicine, 1967 - 1969
Stanford University School of MedicineClass of 1967
Certifications & Licensure
CA State Medical License 1972 - Present
TX State Medical License 1992 - 2025
DC State Medical License 1974 - 1997
MD State Medical License 1974 - 1995- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Elected Member American Association of Physicians, 1991
- Fellow (FASCO) American Society of Clinical Oncologists, 2007
- Elected Member The American Society for Clinical Investigation, 1984
Publications & Presentations
PubMed
- SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition.Xinxin Song, Zhuan Zhou, Ammar Elmezayen, Runliu Wu, Chunhua Yu
Science Advances. 2024-12-13 - ARF alters PAF1 complex integrity to selectively repress oncogenic transcription programs upon p53 loss.Jinli Wang, Nikole L Fendler, Ashutosh Shukla, Shwu-Yuan Wu, Ashwini Challa
Molecular Cell. 2024-12-05 - ASCL1 Restrains ERK1/2 to Promote Survival of a Subset of Neuroendocrine Lung Cancers.Ana Martin-Vega, Svetlana A Earnest, Alexander Augustyn, Chonlarat Wichaidit, Luc Girard
Molecular Cancer Therapeutics. 2024-12-03
Journal Articles
- Retraction Notice to “Sun Exposure Related Methylation in Malignant and Non-Malignant Skin Lesions” [Cancer Letters 245/1-2 (2007) 112-120]John D Minna, Cancer Letters
- Inhibition of thioredoxin/thioredoxin Reductase Induces Synthetic Lethality in Lung Cancers with Compromised Glutathione HomeostasisJohn V Heymach, Stephen G Swisher, Jack A Roth, John D Minna, Clinical Cancer Research
- JAK1/STAT3 Activation Through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non–Small Cell Lung CancerJohn D Minna, Jonathan M Kurie, J Jack Lee, Vassiliki A Papadimitrakopoulou, Neda Kalhor, Roy S Herbst, Clinical Cancer Research
- Join now to see all
Press Mentions
National Cancer Institute Renews $11.5 Million Program of Excellence Award in Kidney CancerSeptember 19th, 2022- Experimental Drug Could Spur Immunotherapy Response in Patients with Non-Small Cell Lung CancerMarch 21st, 2022
- Dan Hayes Witnessed Cancer History, Now He Is Documenting It in a PodcastJune 4th, 2021
- Join now to see all
Grant Support
- Cancer Center Support Grant (CCSG)National Cancer Institute2021–2026
- Vulnerability of SARS-CoV-2 Infection in Lung Cancer Based on Serological Antibody AnalysesNational Cancer Institute2020–2025
- Coordinating Center for Small Cell Lung Cancer U01National Cancer Institute2017–2025
- The University of Texas SPORE (Special Program of Research Excellence) in Lung Cancer Targeting Lung Cancer VulnerabilitiesNational Cancer Institute1996–2025
- Natural Products with Selective Cytoxicity to Non-Small Cell LungNational Cancer Institute2018–2023
- Developing ASCL1 and NeuroD1 lineage oncogene targeted therapy for small cell lung cancerNational Cancer Institute2017–2022
- CA: Administration CoreNational Cancer Institute2008–2011
- University Of Texas Spore In Lung CancerNational Cancer Institute1999–2011
- Spore In Lung CancerNational Cancer Institute2003–2007
- Molecular Pathology Of Lung CancerNational Cancer Institute2005
- Characterization Of Human 3P Recessive OncogenesNational Cancer Institute2001–2004
- Developmental Research ProgramNational Cancer Institute1999–2002
- Career Development ProgramNational Cancer Institute1999–2002
- Identification Of 3P Recessive Oncogenes In Lung CancerNational Cancer Institute1996–2002
- University Of Texas--Spore In Lung CancerNational Cancer Institute1996–1999
- Human 3P Recessive OncogenesNational Cancer Institute1996–1999
- Spore In Lung CancerNational Cancer Institute1992–1994
Professional Memberships
- Fellow
- Member
- Member
- Fellow
- Member
- Member
- American Federation of Clinical Research (AFCR)Member
- International Association for the Study of Lung Cancer (IASLC)Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
